Área Oncología

Grupo de Investigación Translacional de Tumores Sólidos Pediátricos

Samuel Navarro Fos

El Dr. Navarro es licenciado en Medicina y Cirugía por la Facultad de Medicina de la Universitat de València en 1980, donde se doctoró en 1987. Completó su formación con una Beca en Bethesda (USA) realizando investigación en laboratorio de Patología. Actualmente es Catedrático de Anatomía Patológica en la Facultad de Medicina y Odontología en el Departamento de Patología y ha dirigido trece tesis doctorales calificadas con “Sobresaliente Cum Laude”.       

Es coordinador nacional de los estudios anatomopatológicos y de los Protocolos Europeos del Neuroblastoma (SIOP); Miembro del grupo Europeo de patólogos para el estudio del tumor de Ewing (PROTHETS); Miembro de la comisión del banco de tumores de la Red temática de tumores sólidos infantiles (RITSI) e Investigador principal Red temática de Investigación Cooperativa contra el  Cáncer: Tumores pediátricos.

Ha participado en 18 proyectos de I+D, nacionales e internacionales, centrándose su actividad investigadora en la caracterización morfológica, inmunofenotípica y genética de sarcomas indiferenciados de células redondas de hueso y partes blandas.  Su grupo de investigación se ha consolidado como grupo español y europeo de referencia para establecer factores pronósticos fenotípicos y genéticos en los tumores neuroblásticos. También ha participado, como centro de referencia, en los distintos protocolos nacionales y europeos de tratamiento de los tumores neuroblásticos, acorde a las directrices de la SIOP y ha colaborado con laboratorios Europeos (Prof. S. Palman, Universidad de Malmo, Suecia) en estudios de hipoxia y angiogénesis en tumores neuroblásticos. Destaca la aplicación de nuevas tecnologías de alto rendimiento para analizar factores genéticos de valor pronóstico en tumores neuroblásticos. 

 

Grupo de Investigación Translacional de Tumores Sólidos Pediátricos

Técnico

Alejo Miguel Sempere Crespo

Investigador predoctoral

Ana Pilar Berbegall Beltrán
Irene Tadeo Cervera
Maite Blanquer Maceiras
Rebeca Brugos Panadero
Susana Martín Vañó
Víctor Zúñiga Zaragoza

Investigador colaborador

Antonio Llombart Bosch
Rosa Noguera Salvá
  • Análisis genéticos en neuroblastoma. A nivel europeo participamos en el estableciendo de una nomenclatura uniforme, un procedimiento estándar de actuación y estudios de validación de calidad, imprescindibles para obtener y mantener una alta calidad de los resultados de FISH, MLPA y SNPs utilizados para la estratificación terapéutica.
  • Identificación de nuevos factores genéticos con valor pronóstico en los tumores neuroblásticos y esqueletógenos malignos infantiles.
  • Obtención y caracterización de líneas celulares derivadas de tumores en fresco de tumores esqueletógenos infantiles.
  • Establecimiento y caracterización de modelos in vivo de tumores esqueletógenos malignos.
  • Estudios de expresión de marcadores en el carcinoma colorrectal y en tumores sólidos pediatricos.
  • Resultados procedentes del estudio del microambiente tumoral en neuroblastoma.
Número total de publicaciones: 102. Factor de Impacto acumulado: 360.62
High-risk gastrointestinal stromal tumour (GIST) and synovial sarcoma display similar angiogenic profiles: a nude mice xenograft study.
Giner F, Machado I, Lopez-Guerrero JA, Mayordomo-Aranda E, Llombart-Bosch A.
Ecancermedicalscience. 2017. 726
Malignant PEComa With Metastatic Disease at Diagnosis and Resistance to Several Chemotherapy Regimens and Targeted Therapy (m-TOR Inhibitor).
Machado I, Cruz J, Lavernia J, Rayon JM, Poveda A, Llombart-Bosch A.
International journal of surgical pathology. 2017 Apr 1. 1066896917701240. FI: 0.83
Lung metastases from esophageal granular cell tumor: an undoubted criterion for malignancy.
Machado I, Cruz J, Arana E, Peñalver-Cuesta JC, Arraras-Martínez M, Lavernia J, Llombart-Bosch A.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.. 2017 May 12. . FI: 6.595
Expression profiles of angiogenesis in two high grade chondrosarcomas: A xenotransplant experience in nude mice.
Giner F, López-Guerrero JA, Machado I, García-Casado Z, Fernández-Serra A, Peydró-Olaya A, Llombart-Bosch A.
Histology and histopathology. 2017 Feb 3. 11880. FI: 2.025
A stiff extracellular matrix is associated with malignancy in peripheral neuroblastic tumors.
Tadeo I, Berbegall AP, Navarro S, Castel V, Noguera R.
Pediatric blood & cancer. 2017 Sep. . FI: 2.513
Solitary Fibrous Tumor of the Vulva: Report of 2 Cases, Including a De Novo Dedifferentiated Solitary Fibrous Tumor Diagnosed After Molecular Demonstration of NAB2-STAT6 Gene Fusion
Tardío JC, Machado I, Alemany I, López-Soto MV, Nieto MG, Llombart-Bosch A.
International journal of gynecological pathology. 2017 Sep 29. 0277-1691. FI: 1.512
1p36 deletion results in a decrease in glycosaminoglycans which is associated with aggressiveness in neuroblastic tumors
Tadeo I, Gamero-Sandemetrio E, Berbegall AP, Navarro S, Cañete A, Noguera R.
Histology and histopathology. 2017 Nov 23. 11947. FI: 2.025
Distribution of Vascular Patterns in Different Subtypes of Renal Cell Carcinoma. A Morphometric Study in Two Distinct Types of Blood Vessels.
Ruiz-Saurí A, García-Bustos V, Granero E, Cuesta S, Sales MA, Marcos V, Llombart-Bosch A.
Pathology oncology research : POR.. 2017 Jul 1. . FI: 1.736
Ligand-dependent Hedgehog pathway activation in Rhabdomyosarcoma: the oncogenic role of the ligands
Almazán-Moga A, Zarzosa P, Molist C, Velasco P, Pyczek J, Simon-Keller K, Giralt I, Vidal I, Navarro N, Segura MF, Soriano A, Navarro S, Tirado OM, Ferreres JC, Santamaria A, Rota R, Hahn H, Sánchez de Toledo J, Roma J, Gallego S.
British journal of cancer. 2017 Oct. . FI: 6.176
Sinonasal Tract Alveolar Rhabdomyosarcoma in Adults: A Clinicopathologic and Immunophenotypic Study of Fifty-Two Cases with Emphasis on Epithelial Immunoreactivity
Thompson LDR, Jo VY, Agaimy A, Llombart-Bosch A, Morales GN, Machado I, Flucke U, Wakely PE Jr, Miettinen M, Bishop JA.
Head and neck pathology. 2017 Sep 5. 1936-055X
Immunohistochemical analysis of NKX2.2, ETV4, and BCOR in a large series of genetically confirmed Ewing sarcoma family of tumors
Machado I, Yoshida A, López-Guerrero JA, Nieto MG, Navarro S, Picci P, Llombart-Bosch A.
Pathology, research and practice. 2017 Sep. 0344-0338. FI: 1.543
Congenital undifferentiated sarcoma associated to BCOR-CCNB3 gene fusion.
Alfaro-Cervello C, Andrade-Gamarra V, Nieto G, Navarro L, Martín-Vañó S, García de la Torre JP, Bengoa Caamaño M, García Mauriño ML, Noguera R, Navarro S.
Pathology, research and practice. 2017 Jul 14. . FI: 1.543
Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology.
Ibarrola-Villava M, Fleitas T, Llorca-Cardeñosa MJ, Mongort C, Alonso E, Navarro S, Burgues O, Vivancos A, Cejalvo JM, Perez-Fidalgo JA, Roselló S, Ribas G, Cervantes A
Oncotarget. 2016 Apr 19. 22543-55. FI: 5.168
Epigenetic changes in localized gastric cancer: the role of RUNX3 in tumor progression and the immune microenvironment.
Llorca-Cardeñosa MJ, Fleitas T, Ibarrola-Villava M, Peña-Chilet M, Mongort C, Martinez-Ciarpaglini C, Navarro L, Gambardella V, Castillo J, Roselló S, Navarro S, Ribas G, Cervantes A
Oncotarget. 2016 Sep 27. 63424-63436. FI: 5.168
Stage 4S neuroblastoma tumors show a characteristic DNA methylation portrait.
Decock A, Ongenaert M, De Wilde B, Brichard B, Noguera R, Speleman F, Vandesompele J
Epigenetics.. 2016 Sep 6. 0. FI: 4.774
Solitary, multiple, benign, atypical, or malignant: the "Granular Cell Tumor" puzzle.
Machado I, Cruz J, Lavernia J, Llombart-Bosch A
Virchows Archiv: an international journal of pathology.. 2016 May. 527-38. FI: 2.651
The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma.
Bogen D, Brunner C, Walder D, Ziegler A, Abbasi R, Ladenstein RL, Noguera R, Martinsson T, Amann G, Schilling FH, Ussowicz M, Benesch M, Ambros PF, Ambros IM
International journal of cancer. Supplement = Journal international du cancer. Supplement.. 2016 Jul 1. 153-63. FI: 5.085
Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group.
Gronchi A, Stacchiotti S, Verderio P, Ferrari S, Martin Broto J, Lopez-Pousa A, Llombart-Bosch A, Dei Tos AP, Collini P, Jurado JC, De Paoli A, Donati DM, Poveda A, Quagliuolo V, Comandone A, Grignani G, Morosi C, Messina A, De Sanctis R, Bottelli S, Palassini E, Casali PG, Picci P
ESMO open.. 2016 Oct 11. . FI: 9.269
The utility of SATB2 immunohistochemical expression in distinguishing between osteosarcomas and their malignant bone tumor mimickers, such as Ewing sarcomas and chondrosarcomas.
Machado I, Navarro S, Picci P, Llombart-Bosch A
Pathology, research and practice.. 2016 Sep. 811-6. FI: 1.388
Vascular patterns provide therapeutic targets in aggressive neuroblastic tumors.
Tadeo I, Bueno G, Berbegall AP, Fernández-Carrobles MM, Castel V, García-Rojo M, Navarro S, Noguera R
Oncotarget. 2016 Feb 24. . FI: 6.359
BRG1/SMARCA4 is essential for neuroblastoma cell viability through modulation of cell death and survival pathways.
Jubierre L, Soriano A, Planells-Ferrer L, París-Coderch L, Tenbaum SP, Romero OA, Moubarak RS, Almazán-Moga A, Molist C, Roma J, Navarro S, Noguera R, Sánchez-Céspedes M, Comella JX, Palmer HG, Sánchez de Toledo J, Gallego S, Segura MF
Oncogene.. 2016 Mar 21. . FI: 8.459
Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors.
Berbegall AP, Villamón E, Piqueras M, Tadeo I, Djos A, Ambros PF, Martinsson T, Ambros IM, Cañete A, Castel V, Navarro S, Noguera R
Oncogene.. 2016 Mar 17. 1423-32. FI: 8.459
Defining Ewing and Ewing-like small round cell tumors (SRCT): The need for molecular techniques in their categorization and differential diagnosis. A study of 200 cases.
Machado I, Navarro L, Pellin A, Navarro S, Agaimy A, Tardío JC, Karseladze A, Petrov S, Scotlandi K, Picci P, Llombart-Bosch A
Annals of diagnostic pathology.. 2016 Jun. 25-32. FI: 1.117
Diagnostic implications of intrapatient genetic tumor heterogeneity.
Berbegall AP, Navarro S, Noguera R
Molecular & cellular oncology.. 2016 Mar. e1079671
Epithelioid Hemangioma (Angiolymphoid Hyperplasia With Eosinophilia) of the Heart With Peripheral Eosinophilia and Nephrotic Syndrome.
Machado I, Chong A, Serrano A, Naranjo Ugalde AM, Pineda D, Savón L, Olivera E, Llombart-Bosch A
International journal of surgical pathology.. 2016 Feb. 59-65. FI: 0.953
Ewing sarcoma and the new emerging Ewing-like sarcomas: (CIC and BCOR-rearranged-sarcomas). A systematic review.
Machado I, Navarro S, Llombart-Bosch A
Histology and histopathology.. 2016 Nov. 1169-81. FI: 1.875
Extracellular matrix composition defines an ultra-high-risk group of neuroblastoma within the high-risk patient cohort.
Tadeo I, Berbegall AP, Castel V, García-Miguel P, Callaghan R, Påhlman S, Navarro S, Noguera R
British journal of cancer.. 2016 Jul 14. . FI: 5.569
Genetic features of neuroblastic tumors associated with opsoclonus-myoclonus syndrome opens up the possibility for detection in peripheral blood.
Berbegall AP, López-Almaraz R, Navarro S, Noguera R
Expert review of cardiovascular therapy.. 2016 May. 465-7. FI: 2.783
Hyaline globules and papillary fragments in cytologic smears from two intra-abdominal tumors (ovarian and hepatic) in female patients: A diagnostic pitfall with histologic correlation.
Machado I, López-Soto MV, Pérez-López AS, Domínguez-Álvarez C, Llombart-Bosch A
Diagnostic cytopathology.. 2016 Jul 13. . FI: 0.98
Malignant Peripheral Nerve Sheath Tumor With Osseous Heterologous Differentiation in Uncommon Locations (Heart and Retropharynx).
Machado I, Arana E, Cruz J, Brotons S, Vendrell J, Escriba I, Chust ML, Martínez-Banaclocha N, Lavernia J, Llombart-Bosch A
International journal of surgical pathology.. 2016 Feb 16. . FI: 0.953
Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma.
Decock A, Ongenaert M, Cannoodt R, Verniers K, De Wilde B, Laureys G, Van Roy N, Berbegall AP, Bienertova-Vasku J, Bown N, Clément N, Combaret V, Haber M, Hoyoux C, Murray J, Noguera R, Pierron G, Schleiermacher G, Schulte JH, Stallings RL, Tweddle DA, Children’s Cancer and Leukaemia Group (CCLG), De Preter K, Speleman F, Vandesompele J
Oncotarget. 2016 Jan 12. 1960-72. FI: 6.359
miR-200c and phospho-AKT as prognostic factors and mediators of osteosarcoma progression and lung metastasis.
Berlanga P, Muñoz L, Piqueras M, Sirerol JA, Sánchez-Izquierdo MD, Hervás D, Hernández M, Llavador M, Machado I, Llombart-Bosch A, Cañete A, Castel V, Font de Mora J
Molecular oncology.. 2016 Apr 23. . FI: 5.331
Neuroblastoma patient-derived orthotopic xenografts reflect the microenvironmental hallmarks of aggressive patient tumours.
Braekeveldt N, Wigerup C, Tadeo I, Beckman S, Sandén C, Jönsson J, Erjefält JS, Berbegall AP, Börjesson A, Backman T, Øra I, Navarro S, Noguera R, Gisselsson D, Påhlman S, Bexell D
Cancer letters.. 2016 Jun 1. 384-9. FI: 5.621
Comparison of RNA-seq and microarray-based models for clinical endpoint prediction.
Zhang W, Yu Y, Hertwig F, Thierry-Mieg J, Zhang W, Thierry-Mieg D, Wang J, Furlanello C, Devanarayan V, Cheng J, Deng Y, Hero B, Hong H, Jia M, Li L, Lin SM, Nikolsky Y, Oberthuer A, Qing T, Su Z, Volland R, Wang C, Wang MD, Ai J, Albanese D, Asgharzadeh S, Avigad S, Bao W, Bessarabova M, Brilliant MH, Brors B, Chierici M, Chu TM, Zhang J, Grundy RG, He MM, Hebbring S, Kaufman HL, Lababidi S, Lancashire LJ, Li Y, Lu XX, Luo H, Ma X, Ning B, Noguera R, Peifer M, Phan JH, Roels F, Rosswog C, Shao S, Shen J, Theissen J, Tonini GP, Vandesompele J, Wu PY, Xiao W, Xu J, Xu W, Xuan J, Yang Y, Ye Z, Dong Z, Zhang KK, Yin Y, Zhao C, Zheng Y, Wolfinger RD, Shi T, Malkas LH, Berthold F, Wang J, Tong W, Shi L, Peng Z, Fischer M
Genome biology. 2015 Jun 25. 133. FI: 10.288
Deregulation of ARID1A, CDH1, cMET and PIK3CA and target-related microRNA expression in gastric cancer.
Ibarrola-Villava M, Llorca-Cardeñosa MJ, Tarazona N, Mongort C, Fleitas T, Perez-Fidalgo JA, Roselló S, Navarro S, Ribas G, Cervantes A
Oncotarget. 2015 Sep 29. 26935-45. FI: 6.359
Ewing-like sarcoma with CIC-DUX4 gene fusion in a patient with neurofibromatosis type 1. A hitherto unreported association.
Tardío JC, Machado I, Navarro L, Idrovo F, Sanz-Ortega J, Pellín A, Llombart-Bosch A
Pathology, research and practice.. 2015 Nov. 877-82. FI: 1.397
Improved survival in osteosarcoma patients with atypical low vascularization.
Kunz P, Fellenberg J, Moskovszky L, Sápi Z, Krenacs T, Machado I, Poeschl J, Lehner B, Szendrõi M, Ruef P, Bohlmann M, Bosch AL, Ewerbeck V, Kinscherf R, Fritzsching B
Annals of surgical oncology. 2015 Feb. 489-96. FI: 3.93
Individual patient risk stratification of high-risk neuroblastomas using a two-gene score suited for clinical use.
von Stedingk K, De Preter K, Vandesompele J, Noguera R, Øra I, Koster J, Versteeg R, Påhlman S, Lindgren D, Axelson H
International journal of cancer. Journal international du cancer. 2015 Aug 15. 868-77. FI: 5.085
Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification.
Defferrari R, Mazzocco K, Ambros IM, Ambros PF, Bedwell C, Beiske K, Bénard J, Berbegall AP, Bown N, Combaret V, Couturier J, Erminio G, Gambini C, Garaventa A, Gross N, Haupt R, Kohler J, Jeison M, Lunec J, Marques B, Martinsson T, Noguera R, Parodi S, Schleiermacher G, Tweddle DA, Valent A, Van Roy N, Vicha A, Villamon E, Tonini GP
British journal of cancer. 2015 Jan 20. 290-5. FI: 4.836
Intragenic anaplastic lymphoma kinase (ALK) rearrangements: Translocations as a novel mechanism of ALK activation in neuroblastoma tumors.
Fransson S, Hansson M, Ruuth K, Djos A, Berbegall A, Javanmardi N, Abrahamsson J, Palmer RH, Noguera R, Hallberg B, Kogner P, Martinsson T
Genes, chromosomes & cancer. 2015 Feb. 99-109. FI: 4.041
Neuroblastoma patient-derived orthotopic xenografts retain metastatic patterns and geno-and phenotypes of patient tumours.
Braekeveldt N, Wigerup C, Gisselsson D, Mohlin S, Merselius M, Beckman S, Jonson T, Börjesson A, Backman T, Tadeo I, Berbegall AP, Ora I, Navarro S, Noguera R, Påhlman S, Bexell D
International journal of cancer. Journal international du cancer. 2015 Mar 1. E252-61. FI: 5.085
Primary paraesophageal Ewing's sarcoma: an uncommon case report and literature review.
Tarazona N, Navarro L, Cejalvo JM, Gambardella V, Pérez-Fidalgo JA, Sempere A, Navarro S, Cervantes A
OncoTargets and therapy. 2015. 1053-9. FI: 2.311
Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers.
Oberthuer A, Juraeva D, Hero B, Volland R, Sterz C, Schmidt R, Faldum A, Kahlert Y, Engesser A, Asgharzadeh S, Seeger R, Ohira M, Nakagawara A, Scaruffi P, Tonini GP, Janoueix-Lerosey I, Delattre O, Schleiermacher G, Vandesompele J, Speleman F, Noguera R, Piqueras M, Bénard J, Valent A, Avigad S, Yaniv I, Grundy RG, Ortmann M, Shao C, Schwab M, Eils R, Simon T, Theissen J, Berthold F, Westermann F, Brors B, Fischer M
Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Apr 15. 1904-15. FI: 8.722
Soft tissue myoepithelial carcinoma with rhabdoid-like features and EWSR1 rearrangement: Fine needle aspiration cytology with histologic correlation.
Machado I, López-Soto MV, Rubio L, Navarro L, Llombart-Bosch A
Diagnostic cytopathology. 2015 May. 421-6. FI: 1.121
The early stages of tumor angiogenesis in human osteosarcoma: a nude mice xenotransplant model.
Giner F, López-Guerrero JA, Machado I, García-Casado Z, Peydró-Olaya A, Llombart-Bosch A
Virchows Archiv : an international journal of pathology. 2015 Aug. 193-201. FI: 2.651
The Role of Immunohistochemistry in Rhabdomyosarcoma Diagnosis Using Tissue Microarray Technology and a Xenograft Model.
Machado I, Mayordomo-Aranda E, Giner F, Llombart-Bosch A
Fetal and pediatric pathology.. 2015. 271-81. FI: 0.481
Two independent epigenetic biomarkers predict survival in neuroblastoma.
Yáñez Y, Grau E, Rodríguez-Cortez VC, Hervás D, Vidal E, Noguera R, Hernández M, Segura V, Cañete A, Conesa A, Font de Mora J, Castel V
Clinical epigenetics. 2015. 16
Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
García-Alfonso P, García-Foncillas J, Salazar R, Pérez-Segura P, García-Carbonero R, Musulén-Palet E, Cuatrecasas M, Landolfi S, Ramón Y Cajal S, Navarro S, Spanish Society of Pathology, Spanish Society of Medical Oncology
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.. 2015 Apr. 264-73. FI: 2.077
Quantitative modeling of clinical, cellular, and extracellular matrix variables suggest prognostic indicators in cancer: a model in neuroblastoma.
Tadeo I, Piqueras M, Montaner D, Villamón E, Berbegall AP, Cañete A, Navarro S, Noguera R
Pediatric research. 2014 Feb. 302-14. FI: 2.84
Time trends of human papillomavirus types in invasive cervical cancer, from 1940 to 2007.
Alemany L, de Sanjosé S, Tous S, Quint W, Vallejos C, Shin HR, Bravo LE, Alonso P, Lima MA, Guimerà N, Klaustermeier J, Llombart-Bosch A, Kasamatsu E, Tatti SA, Felix A, Molina C, Velasco J, Lloveras B, Clavero O, Lerma E, Laco J, Bravo IG, Guarch R, Pelayo A, Ordi J, Andújar M, Sanchez GI, Castellsagué X, Muñoz N, Bosch FX, RIS HPV TT Study Group
International journal of cancer. Journal international du cancer. 2014 Jul 1. 88-95. FI: 5.007
Reexpression of LSAMP inhibits tumor growth in a preclinical osteosarcoma model.
Barøy T, Kresse SH, Skårn M, Stabell M, Castro R, Lauvrak S, Llombart-Bosch A, Myklebost O, Meza-Zepeda LA
Molecular cancer. 2014 Apr 28. 93. FI: 5.397
3-Deazaneplanocin A (DZNep), an inhibitor of the histone methyltransferase EZH2, induces apoptosis and reduces cell migration in chondrosarcoma cells.
Girard N, Bazille C, Lhuissier E, Benateau H, Llombart-Bosch A, Boumediene K, Bauge C
PloS one. 2014. e98176. FI: 3.534
P16(INK4alpha)/Ki-67 immunocytochemical dual staining for detection of cervical lesions associated to papillomavirus infection.
Toro de Méndez M, Ferrández Izquierdo A, Llombart-Bosch A
Investigación clínica. 2014 Sep. 238-48. FI: 0.492
Neuroblastoma after childhood: prognostic relevance of segmental chromosome aberrations, ATRX protein status, and immune cell infiltration.
Berbegall AP, Villamón E, Tadeo I, Martinsson T, Cañete A, Castel V, Navarro S, Noguera R
Neoplasia (New York, N.Y.). 2014 Jun. 471-80. FI: 5.398
Glycosaminoglycan profiling in different cell types using infrared spectroscopy and imaging.
Brézillon S, Untereiner V, Lovergne L, Tadeo I, Noguera R, Maquart FX, Wegrowski Y, Sockalingum GD
Analytical and bioanalytical chemistry. 2014 Sep. 5795-803. FI: 3.578
The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation.
Brohl AS, Solomon DA, Chang W, Wang J, Song Y, Sindiri S, Patidar R, Hurd L, Chen L, Shern JF, Liao H, Wen X, Gerard J, Kim JS, Lopez Guerrero JA, Machado I, Wai DH, Picci P, Triche T, Horvai AE, Miettinen M, Wei JS, Catchpool D, Llombart-Bosch A, Waldman T, Khan J
PLoS genetics. 2014 Jul. e1004475
Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastoma.
Rihani A, Van Maerken T, De Wilde B, Zeka F, Laureys G, Norga K, Tonini GP, Coco S, Versteeg R, Noguera R, Schulte JH, Eggert A, Stallings RL, Speleman F, Vandesompele J
Pediatric blood & cancer. 2014 Oct. 1867-70. FI: 2.562
Immunoreactivity using anti-ERG monoclonal antibodies in sarcomas is influenced by clone selection.
Machado I, Mayordomo-Aranda E, Scotlandi K, Picci P, Llombart-Bosch A
Pathology, research and practice. 2014 Aug. 508-13. FI: 1.562
Biotensegrity of the extracellular matrix: physiology, dynamic mechanical balance, and implications in oncology and mechanotherapy.
Tadeo I, Berbegall AP, Escudero LM, Alvaro T, Noguera R
Frontiers in oncology. 2014. 39
Anal tuberculosis complicating anti-TNF? therapy.
Luquín N, Masiá M, Noguera R, Gutiérrez F
BMJ case reports. 2014 Nov 24.
Quantification of the heterogeneity of prognostic cellular biomarkers in ewing sarcoma using automated image and random survival forest analysis.
Bühnemann C, Li S, Yu H, Branford White H, Schäfer KL, Llombart-Bosch A, Machado I, Picci P, Hogendoorn PC, Athanasou NA, Noble JA, Hassan AB
PloS one. 2014. e107105. FI: 3.534
Suppression of Deacetylase SIRT1 Mediates Tumor-Suppressive NOTCH Response and Offers a Novel Treatment Option in Metastatic Ewing Sarcoma.
Ban J, Aryee DN, Fourtouna A, van der Ent W, Kauer M, Niedan S, Machado I, Rodriguez-Galindo C, Tirado OM, Schwentner R, Picci P, Flanagan AM, Berg V, Strauss SJ, Scotlandi K, Lawlor ER, Snaar-Jagalska E, Llombart-Bosch A, Kovar H
Cancer research. 2014 Nov 15. 6578-88. FI: 9.284000000000001
CASP8 SNP D302H (rs1045485) Is Associated with Worse Survival in MYCN-Amplified Neuroblastoma Patients.
Rihani A, De Wilde B, Zeka F, Laureys G, Francotte N, Tonini GP, Coco S, Versteeg R, Noguera R, Schulte JH, Eggert A, Stallings RL, Speleman F, Vandesompele J, Van Maerken T
PloS one. 2014. e114696. FI: 3.534
Prevalence of osteoporotic fracture risk factors and antiosteoporotic treatments in the Valencia region, Spain. The baseline characteristics of the ESOSVAL cohort.
Sanfélix-Genovés J, Sanfélix-Gimeno G, Peiró S, Hurtado I, Fluixà C, Fuertes A, Campos JC, Giner V, Baixauli C
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2013 Mar. 1045-55. FI: 4.039
Factors related with symptom duration until diagnosis and treatment of symptomatic colorectal cancer.
Esteva M, Leiva A, Ramos M, Pita-Fernández S, González-Luján L, Casamitjana M, Sánchez MA, Pértega-Díaz S, Ruiz A, Gonzalez-Santamaría P, Martín-Rabadán M, Costa-Alcaraz AM, Espí A, Macià F, Segura JM, Lafita S, Arnal-Monreal F, Amengual I, Boscá-Watts MM, Hospital A, Manzano H, Magallón R, DECCIRE GROUP
BMC cancer. 2013 Feb 23. 87. FI: 3.333
A very rare cancer in Down syndrome: medulloblastoma. Epidemiological data from 13 countries.
Satgé D, Stiller CA, Rutkowski S, von Bueren AO, Lacour B, Sommelet D, Nishi M, Massimino M, Garré ML, Moreno F, Hasle H, Jakab Z, Greenberg M, von der Weid N, Kuehni C, Zurriaga O, Vicente ML, Peris-Bonet R, Benesch M, Vekemans M, Sullivan SG, Rickert C
Journal of neuro-oncology. 2013 Mar. 107-14. FI: 3.115
Galectin-1 (GAL-1) expression is a useful tool to differentiate between small cell osteosarcoma and Ewing sarcoma.
Machado I, López Guerrero JA, Navarro S, Mayordomo E, Scotlandi K, Picci P, Llombart-Bosch A
Virchows Archiv : an international journal of pathology. 2013 Jun. 665-71. FI: 2.676
Hookworm Excretory/Secretory Products Induce Interleukin-4 (IL-4)+ IL-10+ CD4+ T Cell Responses and Suppress Pathology in a Mouse Model of Colitis.
Ferreira I, Smyth D, Gaze S, Aziz A, Giacomin P, Ruyssers N, Artis D, Laha T, Navarro S, Loukas A, McSorley HJ
Infection and immunity. 2013 Jun. 2104-11. FI: 4.074
Chromosomal and genetic changes produced in tumoral progression of embryonal rhabdomyosarcoma.
Gil-Benso R, San-Miguel T, Callaghan RC, Bataller-Calatayud A, Caballero J, Pellín-Carcelén A, Donat J, Navarro S, Peris T, Cerdá-Nicolás M, López-Ginés C
Histopathology. 2013 Apr. 816-9. FI: 2.857
Genetic instability and intratumoral heterogeneity in neuroblastoma with MYCN amplification plus 11q deletion.
Villamón E, Berbegall AP, Piqueras M, Tadeo I, Castel V, Djos A, Martinsson T, Navarro S, Noguera R
PloS one. 2013. e53740. FI: 3.73
Superficial small round-cell tumors with special reference to the Ewing's sarcoma family of tumors and the spectrum of differential diagnosis.
Machado I, Traves V, Cruz J, Llombart B, Navarro S, Llombart-Bosch A
Seminars in diagnostic pathology. 2013 Feb. 85-94. FI: 1.615
NeuPAT: an intranet database supporting translational research in neuroblastic tumors.
Villamón E, Piqueras M, Meseguer J, Blanquer I, Berbegall AP, Tadeo I, Hernández V, Navarro S, Noguera R
Computers in biology and medicine. 2013 Mar 1. 219-28. FI: 1.162
Chronic graft-versus-host disease presenting with coexisting diffuse melanoderma and hypopigmented patches: A peculiar presentation.
Martin-Gorgojo A, Martín JM, Gavrilova M, Monteagudo C, Jordá-Cuevas E
European journal of dermatology : EJD. 2013 Aug 1. 553-5. FI: 1.756
Comments on the ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation.
Coordinadores:, Worner F, Cequier A, Grupo de Trabajo de la Sociedad Española de Cardiología para la guía de práctica clínica sobre el síndrome coronario agudo con elevación del segmento ST:, Bardají A, Bodí V, Bover R, Martínez-Sellés M, Sabaté M, Sionis A, Vázquez de Prada JA, Grupo de Revisores Expertos para la guía de síndrome coronario agudo con elevación del segmento ST:, Arós F, Arribas F, Barrabés J, Díaz de Castro O, Heras M, López Palop R, López-Sendón JL, Manito N, de Pablo MC, Ripoll T, San Román A, de la Torre JM, Comité de Guías de Práctica Clínica de la Sociedad Española de Cardiología:, Fernandez-Ortiz A, Alonso Gómez AM, Anguita M, Cequier A, Comín J, Diaz-Buschmann I, Fernández Lozano I, Gómez de Diego JJ, Pan M, Worner F
Revista española de cardiología. 2013 Jan. 41948. FI: 3.204
Impact of a multidisciplinary team training programme on rectal cancer outcomes in Spain.
Ortiz H, Wibe A, Ciga MA, Lujan J, Codina A, Biondo S, Spanish Rectal Cancer Project
Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland. 2013 May. 544-51. FI: 2.081
snoRNPs Regulate Telomerase Activity in Neuroblastoma and Are Associated with Poor Prognosis.
von Stedingk K, Koster J, Piqueras M, Noguera R, Navarro S, Påhlman S, Versteeg R, Ora I, Gisselsson D, Lindgren D, Axelson H
Translational oncology. 2013 Aug. 447-57. FI: 3.393
Successful carbon dioxide laser treatment for verrucous epidermal nevi on the nipple.
López V, López I, Ricart JM
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]. 2013 Dec. 1936-7. FI: 1.866
Simultaneous purifying selection on the ancestral MC1R allele and positive selection on the melanoma-risk allele V60L in south Europeans.
Martínez-Cadenas C, López S, Ribas G, Flores C, García O, Sevilla A, Smith-Zubiaga I, Ibarrola-Villaba M, Pino-Yanes Mdel M, Gardeazabal J, Boyano D, García de Galdeano A, Izagirre N, de la Rúa C, Alonso S
Molecular biology and evolution. 2013 Dec. 2654-65. FI: 10.353
Roflumilast inhibits respiratory syncytial virus infection in human differentiated bronchial epithelial cells.
Mata M, Martinez I, Melero JA, Tenor H, Cortijo J
PloS one. 2013. e69670. FI: 3.73
Identification of a novel recurrent 1q42.2-1qter deletion in high risk MYCN single copy 11q deleted neuroblastomas.
Fieuw A, Kumps C, Schramm A, Pattyn F, Menten B, Antonacci F, Sudmant P, Schulte JH, Van Roy N, Vergult S, Buckley PG, De Paepe A, Noguera R, Versteeg R, Stallings R, Eggert A, Vandesompele J, De Preter K, Speleman F
International journal of cancer. Journal international du cancer. 2012 Jun 1. 2599-606. FI: 6.198
1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma.
Mackintosh C, Ordóñez JL, García-Domínguez DJ, Sevillano V, Llombart-Bosch A, Szuhai K, Scotlandi K, Alberghini M, Sciot R, Sinnaeve F, Hogendoorn PC, Picci P, Knuutila S, Dirksen U, Debiec-Rychter M, Schaefer KL, de Álava E
Oncogene. 2012 Mar 8. 1287-98. FI: 7.357
Pleomorphic hyalinizing angiectatic tumor: a report of 3 new cases, 1 with sarcomatous myxofibrosarcoma component and another with unreported soft tissue palpebral location.
Illueca C, Machado I, Cruz J, Almenar S, Noguera R, Navarro S, Llombart-Bosch A
Applied immunohistochemistry & molecular morphology : AIMM / official publication of the Society for Applied Immunohistochemistry. 2012 Jan. 96-101
Pathological evaluation of mesocolic resection quality and ex vivo methylene blue injection: what is the impact on lymph node harvest after colon resection for cancer?
Frasson M, Faus C, Garcia-Granero A, Puga R, Flor-Lorente B, Cervantes A, Navarro S, Garcia-Granero E
Diseases of the colon and rectum. 2012 Feb. 197-204. FI: 3.336
Human papillomavirus genotype distribution in cervical cancer cases in Spain. Implications for prevention.
Alemany L, Pérez C, Tous S, Llombart-Bosch A, Lloveras B, Lerma E, Guarch R, Andújar M, Pelayo A, Alejo M, Ordi J, Klaustermeier J, Velasco J, Guimerà N, Clavero O, Castellsagué X, Quint W, Muñoz N, Bosch FX, de Sanjosé S, Spanish study group RIS HPV TT
Gynecologic oncology. 2012 Mar. 512-7. FI: 3.929
Preclinical xenograft models of human sarcoma show nonrandom loss of aberrations.
Kresse SH, Meza-Zepeda LA, Machado I, Llombart-Bosch A, Myklebost O
Cancer. 2012 Jan 15. 558-70. FI: 5.201
Microvessel density is high in clear-cell renal cell carcinomas of Ukrainian patients exposed to chronic persistent low-dose ionizing radiation after the Chernobyl accident.
Romanenko AM, Ruiz-Saurí A, Morell-Quadreny L, Valencia G, Vozianov AF, Llombart-Bosch A
Virchows Archiv : an international journal of pathology. 2012 Jun. 611-9. FI: 2.676
Extracellular matrix, biotensegrity and tumor microenvironment. An update and overview.
Noguera R, Nieto OA, Tadeo I, Fariñas F, Alvaro T
Histology and histopathology. 2012 Jun. 693-705. FI: 2.281
The first European interdisciplinary ewing sarcoma research summit.
Kovar H, Alonso J, Aman P, Aryee DN, Ban J, Burchill SA, Burdach S, De Alava E, Delattre O, Dirksen U, Fourtouna A, Fulda S, Helman LJ, Herrero-Martin D, Hogendoorn PC, Kontny U, Lawlor ER, Lessnick SL, Llombart-Bosch A, Metzler M, Moriggl R, Niedan S, Potratz J, Redini F, Richter GH, Riedmann LT, Rossig C, Schäfer BW, Schwentner R, Scotlandi K, Sorensen PH, Staege MS, Tirode F, Toretsky J, Ventura S, Eggert A, Ladenstein R
Frontiers in oncology. 2012. 54
Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma.
Bennani-Baiti IM, Machado I, Llombart-Bosch A, Kovar H
Human pathology. 2012 Aug. 1300-7. FI: 2.843
Characterization of a new human cell line (CH-3573) derived from a grade II chondrosarcoma with matrix production.
Calabuig-Fariñas S, Benso RG, Szuhai K, Machado I, López-Guerrero JA, de Jong D, Peydró A, San Miguel T, Navarro L, Pellín A, Llombart-Bosch A
Pathology oncology research : POR. 2012 Oct. 793-802. FI: 1.555
Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy.
Stacchiotti S, Verderio P, Messina A, Morosi C, Collini P, Llombart-Bosch A, Martin J, Comandone A, Cruz J, Ferraro A, Grignani G, Pizzamiglio S, Quagliuolo V, Picci P, Frustaci S, Dei Tos AP, Casali PG, Gronchi A
Cancer. 2012 Dec 1. 5857-66. FI: 5.201
Epithelial cell adhesion molecules and epithelial mesenchymal transition (EMT) markers in Ewing's sarcoma family of tumors (ESFTs). Do they offer any prognostic significance?
Machado I, López-Guerrero JA, Navarro S, Alberghini M, Scotlandi K, Picci P, Llombart-Bosch A
Virchows Archiv : an international journal of pathology. 2012 Sep. 333-7. FI: 2.676
Exon-level expression analyses identify MYCN and NTRK1 as major determinants of alternative exon usage and robustly predict primary neuroblastoma outcome.
Schramm A, Schowe B, Fielitz K, Heilmann M, Martin M, Marschall T, Köster J, Vandesompele J, Vermeulen J, de Preter K, Koster J, Versteeg R, Noguera R, Speleman F, Rahmann S, Eggert A, Morik K, Schulte JH
British journal of cancer. 2012 Oct 9. 1409-17. FI: 5.082
Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers.
Decock A, Ongenaert M, Hoebeeck J, De Preter K, Van Peer G, Van Criekinge W, Ladenstein R, Schulte JH, Noguera R, Stallings RL, Van Damme A, Laureys G, Vermeulen J, Van Maerken T, Speleman F, Vandesompele J
Genome biology. 2012 Oct 3. R95. FI: 9.036
Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project.
Schleiermacher G, Mosseri V, London WB, Maris JM, Brodeur GM, Attiyeh E, Haber M, Khan J, Nakagawara A, Speleman F, Noguera R, Tonini GP, Fischer M, Ambros I, Monclair T, Matthay KK, Ambros P, Cohn SL, Pearson AD
British journal of cancer. 2012 Oct 9. 1418-22. FI: 5.082
Pulmonary artery sarcoma with angiosarcoma phenotype mimicking pleomorphic malignant fibrous histiocytoma: a case report.
Bohn OL, León EA, Lezama O, Rios-Luna NP, Sánchez-Sosa S, Llombart-Bosch A
Diagnostic pathology. 2012 Nov 7. 154. FI: 1.85
Three new chondrosarcoma cell lines: one grade III conventional central chondrosarcoma and two dedifferentiated chondrosarcomas of bone.
van Oosterwijk JG, de Jong D, van Ruler MA, Hogendoorn PC, Dijkstra PS, van Rijswijk CS, Machado I, Llombart-Bosch A, Szuhai K, Bovée JV
BMC cancer. 2012 Aug 28. 375. FI: 3.333
Uterine glomeruloid hemangioma in a patient without POEMS syndrome.
Giner F, Compañ A, Monteagudo C
International journal of surgical pathology. 2012 Aug. 407-10. FI: 0.756
Guidelines for biomarker testing in colorectal carcinoma (CRC): a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM).
García-Alfonso P, Salazar R, García-Foncillas J, Musulén E, García-Carbonero R, Payá A, Pérez-Segura P, Ramón y Cajal S, Navarro S
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2012 Oct. 726-39. FI: 1.276
An integrated analysis of miRNA and gene copy numbers in xenografts of Ewing's sarcoma.
Mosakhani N, Guled M, Leen G, Calabuig-Fariñas S, Niini T, Machado I, Savola S, Scotlandi K, López-Guerrero JA, Llombart-Bosch A, Knuutila S
Journal of experimental & clinical cancer research : CR. 2012 Mar 20. 24
Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.
Baselga J, Segalla JG, Roché H, Del Giglio A, Pinczowski H, Ciruelos EM, Filho SC, Gómez P, Van Eyll B, Bermejo B, Llombart A, Garicochea B, Durán MÁ, Hoff PM, Espié M, de Moraes AA, Ribeiro RA, Mathias C, Gil Gil M, Ojeda B, Morales J, Kwon Ro S, Li S, Costa F
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 May 1. 1484-91. FI: 18.038
New prognostic markers in neuroblastoma.
Navarro S, Piqueras M, Villamón E, Yáñez Y, Balaguer J, Cañete A, Noguera R
Expert opinion on medical diagnostics. 2012 Nov. 555-67

Búsqueda de dianas terapéuticas en los puntos de contacto de la célula tumoral en el neuroblastoma infantil con su matriz extracelular

Referencia:
FAECC2015
Investigador principal:
Rosa Noguera Salvá
Entidad financiadora:
AECC-Asociación Española Contra el Cáncer
Duración:
01/01/2015 - 31/12/2018
Presupuesto total:
€150.000

Estudio de la biotensegridad en los tumores neuroblásticos.

Referencia:
PI14/01008
Investigador principal:
Rosa Noguera Salvá
Entidad financiadora:
Instituto de Salud Carlos III
Duración:
01/01/2015 - 31/12/2017
Presupuesto total:
€101.500

Búsqueda de dianas terapéuticas en los puntos de contacto de la célula tumoral en el neuroblastoma infantil con su matriz extracelular. Estudio piloto.

Referencia:
VLC BIOCLINIC NEUBLAFIB
Investigador principal:
Rosa Noguera Salvá
Entidad financiadora:
Universidad de Valencia
Duración:
01/01/2015 - 31/12/2015
Presupuesto total:
€4.000

aSNP analysis of DNA alterations in neuroblastic tumors

Referencia:
31514
Investigador principal:
Rosa Noguera Salvá
Entidad financiadora:
Fundación NEN, Amigos y Familiares de Enfermos de Neuroblastoma
Duración:
01/01/2015 - 31/12/2015
Presupuesto total:
€6.000

Búsqueda de dianas terapéuticas en los puntos de contacto de la célula tumoral en el neuroblastoma infantil con su matriz extracelular. Estudio piloto.

Referencia:
VLC-BIOCLINIC Subprograma B1
Investigador principal:
Rosa Noguera Salvá
Entidad financiadora:
Universidad de Valencia
Duración:
01/01/2015 - 31/12/2015
Presupuesto total:
€4.000

Modelo in silico de la hiperestructura de los tumores neuroblásticos. Integración génica, microscópica y clínica

Referencia:
ACOMP/2012/087
Investigador principal:
Rosa Noguera Salvá
Entidad financiadora:
Generalitat Valenciana. Conselleria d'Educació Cultura i Esport
Duración:
30/01/2012 - 30/06/2012
Presupuesto total:
€14.000

Teatro para apoyar la investigación oncológica

El grupo Valentes i positives financiará INCLIVA para luchar contra el cáncer de mama y el cáncer infantil.

 

Publicado el 06/06/2018.Leer más »

Un estudio de INCLIVA abre camino a nuevos tratamientos personalizados del neuroblastoma

Los resultados de esta investigación plantean nuevos tratamientos para neuroblastomas y otros tumores sólidos pediátricos

Publicado el 14/05/2018.Leer más »

INCLIVA y la Asociación NEN firman un acuerdo para luchar contra el neuroblastoma

La Asociación NEN aportará 57.000 euros para la investigación del neuroblastoma

Publicado el 28/03/2018.Leer más »

Identifican el mecanismo de activación de la vía Hedgehog implicada en el rabdomiosarcoma, un tipo de cáncer infantil

En modelos animales de experimentación observaron que cuando las células no tienen los ligandos, los tumores no podían crecer o su crecimiento era muy limitado.

Publicado el 08/11/2017.Leer más »

La Investigación de sarcoma de Ewing de Cris podría desvelar que las alteraciones genéticas pueden pronosticar la evolución de esta enfermedad

La Fundación CRIS Contra el Cáncer cree firmemente que la investigación tienen que hacerse a largo plazo para obtener resultado, por ello, apoyará tres años más, el Proyecto de Sarcoma de Ewing con una financiación de 120.000 euros. 

 

Publicado el 28/02/2017.Leer más »

La organización de las fibras de reticulina influye en la agresividad de los tumores infantiles neuroblásticos

El neuroblastoma es el tumor sólido extracraneal más frecuente en los niños y en España se diagnostican entre 70 y 100 niños menores de 14 años cada año.

Publicado el 11/08/2016.Leer más »

La iniciativa gallega “Nico contra el cáncer” apoya a INCLIVA en la investigación de los tumores infantiles.

Tras colaborar con la Dra. Noguera en Precipita, ahora donan diez mil euros más.

Publicado el 09/05/2016.Leer más »

El primer proyecto de INCLIVA en Precipita, record de financiación

La dirección del Instituto y del Grupo de Investigación de la Dra. Noguera, agradecen la colaboración de la plataforma Precipita en la difusión del proyecto y a todos los que han realizado una aportación al proyecto

Publicado el 29/01/2016.Leer más »